CNSP

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing treatments for primary and metastatic cancers of the brain and central nervous system. Headquartered in Houston, Texas, the company's lead product candidate is Berubicin, a novel anthracycline designed to treat glioblastoma multiforme, an aggressive and difficult-to-treat brain cancer. Berubicin is engineered to cross the blood-brain barrier more effectively than traditional chemotherapy drugs and accumulate in brain tumor tissue. CNS Pharmaceuticals is conducting clinical trials to evaluate Berubicin's safety and efficacy in patients with recurrent glioblastoma. The company aims to address significant unmet medical needs in neuro-oncology where treatment options remain limited and survival rates are poor.